Journal
ANAEROBE
Volume 60, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.anaerobe.2019.102092
Keywords
Clostridioides difficile; Clostridium difficile; Fecal microbiota transplant; Recurrence
Categories
Funding
- US Department of Veterans Affairs Research Service
Ask authors/readers for more resources
Despite lack of regulatory approval, fecal microbiota transplantation (FMT) is widely performed to manage C. difficile infection (CDI), particularly recurrent CDI. Herein, we critically review the available randomized controlled trials of FMT and address the following questions: Is FMT better than drug management of recurrent CDI?; Is FMT treatment per se or adjunctive treatment to antibiotics for CDI?; and, Is FMT safe? Finally, we elaborate non-FMT options for the management of recurrent CDI. Although promising, FMT should be reserved for patients who have failed appropriate antibiotic management of recurrent CDI. (C) 2019 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available